Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

Summary

Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA). The goal is to see if a shorter treatment schedule is as safe and effective as the standard schedule. Why is this study important? After prostate surgery, cancer can return in up to 70-80% of high-risk patients. Radiotherapy helps control this, but the best way to deliver it-especially the number of sessions and whether to treat the pelvic area-is still being studied. Shorter treatments could mean less time in therapy and better quality of life, if such treatments are proven safe. What is being compared? Standard treatment (Arm A): 25 sessions (about 5 weeks) Prostate bed: 62.5 Gy Pelvis: 45 Gy Shorter treatment (Arm B): 20 sessions (about 4 weeks) Prostate bed: 52.5 Gy Pelvis: 43 Gy Both groups may also receive hormone therapy (ADT) for 6-24 months. Main Goal To check if the shorter treatment causes no more side effects (urinary or bowel problems) than the standard treatment, while keeping cancer control similar. Other Things to be Measured Cancer control (PSA levels, spread of disease) Survival Quality of life (urinary, bowel, sexual health questionnaires) Who can join? Men who: Had prostate surgery Have a detectable PSA (≥0.2 ng/mL) No distant metastasis Are in good general health (ECOG 0-2) How long will the study last? About 12 years total: 2 years to enroll patients 10 years of follow-up

Eligibility

Inclusion Criteria:

* Histologically confirmed prostate adenocarcinoma.
* Prior radical prostatectomy with detectable PSA (≥0.2 ng/mL).
* No evidence of distant metastasis (confirmed via bone scan and CT/MRI or TEP-PSMA if PSA is above 0.5 ng /ml).
* Patient with Nodal recurrence within the pelvis are eligible
* ECOG performance status 0-2.
* Age ≥ 18 years.
* Adequate baseline renal, hepatic, and hematologic function.

Exclusion Criteria:

* Prior pelvic radiotherapy.
* Macroscopic local relapse on imaging
* Presence of metastatic disease.
* Active inflammatory bowel disease or other GI conditions predisposing to radiation toxicity.
* Uncontrolled comorbidities affecting study participation.
* Prior systemic therapy for recurrent prostate cancer (except ADT within 6 months).

Conditions7

Interventions1

Related trials

• A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer — University College, London
• Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial) — German Oncology Center, Cyprus
• PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer — Affidea Nu-med Center of Oncological DIagnostics and Therapy
• PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer — Affidea Nu-med Center of Oncological DIagnostics and Therapy
• Radiotherapy After Prostatectomy for Node Positive Prostate Cancer — Sun Yat-sen University
• Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation — AstraZeneca

Browse More Trials